Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

This phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myelom

Trial Details

NCT ID

NCT06785415

Phase

PHASE1 / PHASE2

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Bone Marrow Aspiration
Bone Marrow Biopsy
Bone Scan
Chest Radiography
Computed Tomography
Daratumumab

Locations (sample)

Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

Age ≥ 18 years at the time of signing the informed consent form (ICF).
Diagnosis of relapsed multiple myeloma with ≤ 3 prior lines of therapy including treatment with proteasome inhibitors (i.e., ixazomib, carfilzomib,…
Note: Prior treatment with iberdomide is not allowed. Patients should not be refractory simultaneously to all other drugs in the combination.
Measurable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →